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ontinuous-flow ventricular assist devices (CVADs) are
more compact, less costly, and potentially more durable
than pulsatile ventricular assist devices (PVADs). How-
ever, studies in animal models suggest that long-term
continuous-flow support can result in hemodynamic dysfunction.
This includes the disruption of the renin-angiotensin system1 and
the response to norepinephrine administration in comparison with
PVADs.2 The purpose of this study was to determine whether
CVAD insertion and duration of CVAD support was associated
with greater hemodynamic compromise after return to pulsatility af-
ter device explantation and heart transplantation.
Clinical Summary
We retrospectively reviewed 44 consecutive patients undergoing
heart transplantation/ventricular assist device (VAD) explantation
at our institution. These included 33 PVADs and 11 CVADs. All pa-
tients in the study had NewYork Heart Association stage IV conges-
tive heart failure at the time of LVAD insertion and were
successfully bridged to transplantation with no mortality on the de-
vice. Doses of all continuously infused pressors administered to pa-
tients for 7 postoperative days were collected. The degree of
pressors and inotropic support was assessed by using a composite
pressor/inotropic score (Table 1) that accounted for all concurrently
administered vasoactive medications. To test our hypothesis that de-
gree of hemodynamic dysfunction was directly related to duration of
CVAD support, the CVAD and PVAD groups were further subdi-
vided by using median duration of CVAD support (94 days):
CVAD support for 94 days or longer (group 1, n5 6); CVAD sup-
port for less than 94 days (group 2, n 5 5); PVAD support for 94
days or longer (group 3, n 5 11); and PVAD support for less than
94 days (group 4, n 5 22).
All patients were comparable in their preoperative characteristics
with no significant differences, including age (group 1, 56 6 7.3
years; group 2, 406 10 years; group 3, 496 13.6 years; and group
4, 536 11 years;P5 .07), preoperative incidence of diabetes, hyper-
tension, and hepatic and renal functions.Mean duration of donor heart
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2416 27minutes; group 3, 1856 41minutes; and group 4, 1906 45
minutes (P5 .2). During the 7-day period after heart transplantation/
VAD explantation, patients supported by CVADs had significantly
higher composite scores at all time points comparedwith patients sup-
ported by PVADs. Among CVAD recipients, there was a direct and
statistically significant relationship between duration ofVAD support
and composite score at all time points. Compared with patients on
CVAD support for less than 94 days (group 2), PVAD support for
94 days or longer (group 3), and PVAD support for less than 94
days (group 4), patients with CVAD support for 94 days or longer
(group 1) had significantly higher composite scores during the 7-
day period after heart transplantation (Figure 1). Nevertheless, there
was no statistical difference in 30-day posttransplantation mortality
between the groups. All patients receiving CVADs survived for 30
days after transplantation, whereas only 2 patients died in the
PVAD group.
Discussion
These findings suggest that longer duration of CVAD support is as-
sociated with greater hemodynamic compromise, as demonstrated
by the need for higher dose requirements and increased duration
of pressor support after restoration of pulsatility.
This study is consistent with findings from previous studies that
suggest changes in vascular tone and structure associated with pe-
riods of nonpulsatile flow. Studies in animal models demonstrate
that nonpulsatile flow is associated with alternations in vascular
tone. Systemic vascular resistance has also been shown to decrease
significantly in nonpulsatile flow, despite pressor administration.
Nishimura and colleagues2 reported a more pronounced decrease
in vascular resistance in a large-animal model after 4 weeks of non-
pulsatile support compared with that seen in animals treated with 2
weeks of nonpulsatile support. Similarly, continuous circulatory
support has been shown to be associated with histologic changes
in myocardial and endothelial tissue.3 Westaby and associates4 re-
cently reported a significant decrease in arterial medial wall thick-
ness after prolonged support with continuous flow devices, an
effect that was associated with a decrease in smooth muscle cells
and medial layer elastin content.
This is a preliminary study and has a number of limitations. First,
it was retrospective in nature, and therefore the patient population
might differ. Because continuous-flow devices are limited to pa-
tients enrolled in clinical trials, it is in fact likely that the patients re-
ceiving CVADs were less severely ill than those receiving PVADs;
however, a comparison of baseline characteristics did not reveal any
statistically significant differences between the groups. Further-
more, the composite pressor score was developed by another group
of investigators for application in a non-VAD/nontransplant heart
failure population5; this score has yet to be validated.ust 2008
Brief CommunicationsFurther studies are needed to investigate these findings. This
includes repeating the analysis on other, larger patient populations;
examination of other hemodynamic measures, including systemic
vascular resistance, myocardial oxygen consumption, and cardiac
index; the use of gene array and serum enzyme-linked immunosor-
bent assay techniques to identify changes in gene expression pat-
terns during and after periods of VAD support; and examination
of changes of vascular structure by using techniques such as radial
artery biopsy during and after periods of CVAD support.
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TABLE 1. Composite pressor score
Medication 0 points 1 point 2 points 3 points
Milrinone (mcg/kg/min) 0.0 ,0.375 0.375–5 $0.5
Norepinephrine
(mcg/kg/min)
0.0 ,5 5–10 .10
Epinephrine (mcg/kg/min) 0.0 ,0.1 0.1–0.4 $0.4
Dopamine (mcg/kg/min) 0.0 ,4 4–10 .10
Dobutamine (mcg/kg/min) 0.0 ,5 5–10 .10
Phenylephrine (mcg/kg/min) 0.0 0.2 0.3 0.4
Vasopressin (U) 0.0 ,2 2–4 .4Superficial femoral vein as substitute
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Figure 1. Composite pressor score by ventricular assist device du-
ration and type. PVAD, Pulsatile ventricular assist device; CVAD,
continuous-flow ventricular assist device.for pulmonary artery
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pe Pasche, MD,b L. Magnusson, MD,c and
P
ost-lobectomy bronchovascular fistula (BVF) associated
with massive hemoptysis is a rare but life-threatening com-
plication. Surgical options include completion pneumo-
nectomy or BVF resection with end-to-end anastomosis
of the airways and reconstruction of the pulmonary artery (PA) by
interposition of an appropriate substitute. We report PA resection
and successful reconstruction by interposition of an autologous
reversed superficial femoral vein (SFV) segment for this purpose.
Clinical Summary
A 59-year-old man with a history of coronary stenting for coronary
artery disease underwent uncomplicated intrapericardial left upper
lobectomy after radiochemotherapy (60 Gy) for non–small cell
lung cancer. Two months later, cataclysmal hemoptysis developed
in the patient, requiring cardiopulmonary reanimation, bedside rigid
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